Keros Therapeutics Inc (NASDAQ: KROS) — Perfil da empresa, notícias e dados financeiros
Keros Therapeutics develops innovative treatments for hematological and musculoskeletal disorders using TGF-beta proteins.
Keros Therapeutics Inc
Keros Therapeutics (NASDAQ:KROS) is a biotechnology company focused on the development of innovative treatments for hematological and musculoskeletal disorders with high unmet medical needs. Through its pioneering research in transforming growth factor-beta (TGF-beta) family proteins, Keros aims to address diseases characterized by low blood cell counts, bone disorders, and muscular dystrophies. Their portfolio includes flagship projects such as KER-050 for the treatment of anemia and thrombocytopenia, and KER-047 designed to target fibrodysplasia ossificans progressiva and anemia of chronic disease. The company's objective is to leverage its deep understanding of TGF-beta protein mechanisms to advance a pipeline of novel therapeutics that can significantly improve patient outcomes and quality of life.
Resumo
Operações
Produtos e/ou serviços de Keros Therapeutics Inc
- Development of KER-050 for treating myelodysplastic syndromes and myelofibrosis, focusing on hematopoiesis enhancement.
- Exploring KER-047 for treating anemia of chronic disease and iron homeostasis disorders, aimed at improving patients' quality of life.
- Advancement of KER-012 for treating pulmonary arterial hypertension and certain types of heart failure, focusing on cardiovascular disease management.
- Innovative approaches in treating bone disorders and hematological conditions, leveraging proprietary technology for novel therapeutics.
- Collaboration with pharmaceutical companies for the development and commercialization of therapies in bone disease and hematologic disorders.
- Continuous research and development efforts aimed at expanding the pipeline with therapies targeting rare diseases and complex conditions.
equipe executiva do Keros Therapeutics Inc
- Jasbir S. SeehraPresident, CEO & Director
- Esther ChoChief Legal Officer & Secretary
- Annita TaniniVP of Finance, Corporate Controller and Interim Principal Financial & Accounting Officer
- Justin FrantzHead of Investor Relations
- Lorena LernerChief Scientific Officer
Principais indicadores financeiros
Resultados divulgados pela Keros Therapeutics Inc, em USD.
- Cap. de mercado
- 230,2 mi
- Receita (TTM)
- 15 mi
- P/L
- —
- LPA (diluído, TTM)
- -3.3
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 244,1 mi | 70,6 mi | 87 mi | |
| 3,6 mi | -210,8 mi | -187,4 mi | |
| 151 mil | -169,9 mi | -153 mi | |
| 20 mi | -114,8 mi | -104,7 mi |